Sun Pharma Q3 net up 32%

  • HT Correspondent, Hindustan Times, Mumbai
  • |
  • Updated: Feb 08, 2013 21:20 IST

Sun Pharmaceutical Inds on Friday announced a 32% year-on-year growth in consolidated net profit to Rs 881.30 crore for the quarter ended December from Rs 668.30 crore in the same period a year ago, driven by strong sales in the United States market.

Sales of branded prescription formulations in US rose 44% to Rs 1,495 crore from Rs 1,040 crore in the same quarter previous year. The US sales accounted for 52% of total sales during the quarter.

"All our businesses continue to perform in-line with our expectations. The acquisition of DUSA and URL's generic business will further strengthen our presence in the US," said Dilip Shanghvi, MD, Sun Pharmaceutical.

US-based Dusa, a dermatology company, was acquired by Sun pharma for around R1,250 crore last year. Caraco Pharma, Sun Pharma's wholly-owned subsidiary, also announced the acquisition of URL Pharma Inc's generic business in US, during the quarter.

 

also read

Struggling BlackBerry announces new round of layoffs

blog comments powered by Disqus